MA37931A1 - Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite - Google Patents
Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduiteInfo
- Publication number
- MA37931A1 MA37931A1 MA37931A MA37931A MA37931A1 MA 37931 A1 MA37931 A1 MA 37931A1 MA 37931 A MA37931 A MA 37931A MA 37931 A MA37931 A MA 37931A MA 37931 A1 MA37931 A1 MA 37931A1
- Authority
- MA
- Morocco
- Prior art keywords
- treating cancer
- improved methods
- renal toxicity
- reduced renal
- cancer patient
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 5
- 201000011510 cancer Diseases 0.000 title abstract 4
- 238000000034 method Methods 0.000 title abstract 3
- 231100000417 nephrotoxicity Toxicity 0.000 title 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 229940044683 chemotherapy drug Drugs 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne un procédé permettant d'empêcher la croissance d'une tumeur chez un patient atteint d'un cancer ou de traiter un patient atteint d'un cancer, le patient atteint d'un cancer présentant une insuffisance rénale. Le procédé nécessite l'administration d'une quantité efficace de lipoplatine. Un second médicament chimiothérapique peut également être administré au patient. La seconde chimiothérapie peut être administrée avant ou après la thérapie par lipoplatine ou simultanément.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2012/050630 WO2014027996A1 (fr) | 2012-08-13 | 2012-08-13 | Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA37931A1 true MA37931A1 (fr) | 2016-07-29 |
Family
ID=50101360
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37931A MA37931A1 (fr) | 2012-08-13 | 2012-08-12 | Procédés améliorés permettant de traiter un cancer avec une toxicité rénale réduite |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20150258140A1 (fr) |
| EP (1) | EP2882420A4 (fr) |
| JP (1) | JP2015528446A (fr) |
| CN (1) | CN104736143A (fr) |
| AU (1) | AU2012387681A1 (fr) |
| BR (1) | BR112015003111A2 (fr) |
| CA (1) | CA2882156A1 (fr) |
| EA (1) | EA201590325A1 (fr) |
| IN (1) | IN2015KN00375A (fr) |
| MA (1) | MA37931A1 (fr) |
| SG (1) | SG11201501146VA (fr) |
| WO (1) | WO2014027996A1 (fr) |
| ZA (1) | ZA201501123B (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ728724A (en) * | 2012-05-11 | 2018-03-23 | Reset Therapeutics Inc | Carbazole-containing sulfonamides as cryptochrome modulators |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH04169532A (ja) * | 1990-11-01 | 1992-06-17 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金錯体含有リポソーム製剤 |
| JPH04169531A (ja) * | 1990-11-01 | 1992-06-17 | Sumitomo Pharmaceut Co Ltd | 脂溶性白金錯体を含有するリポソーム製剤 |
| EP0551169A1 (fr) * | 1992-01-10 | 1993-07-14 | Takeda Chemical Industries, Ltd. | Composition de liposome et procédé de préparation |
| ATE252372T1 (de) * | 1996-08-23 | 2003-11-15 | Sequus Pharm Inc | Liposome enthaltend cisplatin |
| DE19954613A1 (de) * | 1999-11-12 | 2001-05-17 | Enthone Omi Deutschland Gmbh | Verfahren zur stromlosen Verzinnung von Kupfer oder Kupferlegierungen |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| GR20060100144A (el) * | 2006-03-03 | 2007-10-17 | Θεραπεια του καρκινου με χρηση οξαλιπλατινης εγκλεισμενης μεσα σε λιποσωματα και απο κοινου εγκλεισμος στο λιποσωμιακο μοριο περισσοτερων απο ενος φαρμακευτικου παρασκευασματος h gene | |
| EP2123258A1 (fr) * | 2008-05-23 | 2009-11-25 | Liplasome Pharma A/S | Liposomes pour l'administration de médicaments |
| US20120197060A1 (en) * | 2009-06-18 | 2012-08-02 | University Of Utah Research Foundation | Radiation enhanced macromolecular delivery of therapeutic agents for chemotherapy technology |
-
2012
- 2012-08-12 MA MA37931A patent/MA37931A1/fr unknown
- 2012-08-13 WO PCT/US2012/050630 patent/WO2014027996A1/fr not_active Ceased
- 2012-08-13 IN IN375KON2015 patent/IN2015KN00375A/en unknown
- 2012-08-13 SG SG11201501146VA patent/SG11201501146VA/en unknown
- 2012-08-13 AU AU2012387681A patent/AU2012387681A1/en not_active Abandoned
- 2012-08-13 CN CN201280075225.2A patent/CN104736143A/zh active Pending
- 2012-08-13 CA CA2882156A patent/CA2882156A1/fr not_active Abandoned
- 2012-08-13 EA EA201590325A patent/EA201590325A1/ru unknown
- 2012-08-13 JP JP2015527429A patent/JP2015528446A/ja active Pending
- 2012-08-13 EP EP12883054.4A patent/EP2882420A4/fr not_active Withdrawn
- 2012-08-13 BR BR112015003111A patent/BR112015003111A2/pt not_active IP Right Cessation
- 2012-08-13 US US14/421,392 patent/US20150258140A1/en not_active Abandoned
-
2015
- 2015-02-18 ZA ZA2015/01123A patent/ZA201501123B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2882420A4 (fr) | 2016-06-01 |
| ZA201501123B (en) | 2020-02-26 |
| JP2015528446A (ja) | 2015-09-28 |
| CA2882156A1 (fr) | 2014-02-20 |
| BR112015003111A2 (pt) | 2017-10-10 |
| CN104736143A (zh) | 2015-06-24 |
| IN2015KN00375A (fr) | 2015-07-10 |
| SG11201501146VA (en) | 2015-05-28 |
| AU2012387681A1 (en) | 2015-03-05 |
| EA201590325A1 (ru) | 2015-09-30 |
| WO2014027996A1 (fr) | 2014-02-20 |
| US20150258140A1 (en) | 2015-09-17 |
| EP2882420A1 (fr) | 2015-06-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1251157A1 (zh) | 使用ACTRII配体陷阱治疗β-地中海贫血 | |
| WO2012159085A3 (fr) | Compositions et méthodes de traitement et de prévention du cancer par ciblage et inhibition de cellules souches cancéreuses | |
| WO2018094190A3 (fr) | Microbiote intestinal et traitement du cancer | |
| WO2009111691A3 (fr) | Thérapie combinée par des antagonistes de c-met et egfr | |
| WO2017176628A8 (fr) | Méthodes de traitement de tumeurs solides | |
| WO2013052699A3 (fr) | Nouveaux inhibiteurs de quinoxaline de la voie pi3k | |
| EP2294184A4 (fr) | Traitement de maladies oculaires et d une néovascularisation excessive utilisant un traitement combiné | |
| BRPI0908635B8 (pt) | composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica | |
| WO2011127333A3 (fr) | Composés pour le traitement d'une maladie, pour l'administration, et pour des compositions pharmaceutiques | |
| MX360877B (es) | Compuesto 1-etil-7-(2-metil-6-(1h-1,2,4-triazol-3-il)piridin-3-il) -3,4-dihidropirazino[2,3-b]pirazin-(1h)-ona para usarse en el tratamiento de sarcoma de ewing que sobreexpresa e-veintiseis(ets). | |
| BR112012029280A2 (pt) | variante de domínio variável único de imunoglobulina antialbumina sérica, imunoglobulina anti-sa, ligando multiespecífico, proteína de fusão, composição, ácido nucleico, vetor, célula hospedeira isolada, e, uso de uma variante, ligando multiespecífico ou proteína de fusão | |
| WO2012141796A3 (fr) | Traitement du cancer de la prostate avec des composés inhibiteurs de hsp90 | |
| EA201290517A1 (ru) | Гетероароматические арилтриазольные производные в качестве ингибиторов фермента pde10a | |
| EA201591987A1 (ru) | Лечение злокачественной опухоли дигидропиразинопиразинами | |
| AU2013218357A8 (en) | Tetrahydro-quinazolinone derivatives as TANK and PARP inhibitors | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| EA201992513A1 (ru) | Способ лечения рака груди | |
| WO2013095286A3 (fr) | Combinaison synergique pour l'inhibition d'une tumeur | |
| HK1211203A1 (en) | Injectable cancer compositions | |
| GB201013785D0 (en) | Treatment | |
| MX2014014816A (es) | Composicion farmaceutica para tratar inflamacion y dolor. | |
| RU2013130449A (ru) | Способ комбинированного лечения рака прямой кишки | |
| EA201590325A1 (ru) | Улучшенные способы лечения рака с пониженной почечной токсичностью | |
| WO2012158776A3 (fr) | Thérapie d'association pour le traitement du cancer | |
| Tamaru | Thrombocytopenia, neutropenia and hypertension: case report |